Navigation Links
Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
Date:12/4/2007

AGAWAM, Mass., Dec. 4 /PRNewswire/ -- A new, free white paper, addressing the challenges of new U.S. Food and Drug Administration (FDA) regulations awaiting combination products manufacturers, is now available for download at http://www.microtestlabs.com/combinationpaper.

While combination products are experiencing dramatic growth, the convergence of drug/biologics and devices brings a host of regulatory challenges. Manufacturers must ensure their products meet cGMP practices as well as pass muster with the FDA, ISO, and USP.

Steven Richter, Ph.D., Microtest President & Chief Scientific Officer, addresses the critical issues associated with this complex process, including defining the FDA's regulatory framework, reviewing developments in FDA thinking, and identifying future considerations in developing effective quality assurance systems.

"The combination products market -- medical devices embedded with pharmaceutical or biologics components -- is rapidly moving forward with a new direction and emphasis regarding product safety and FDA requirements," said Richter, who is author of the announced white paper, "Combination Products: Navigating Two FDA Quality Systems."

Navigant consulting, estimating the combination products market at $5.9 billion in 2004, predicts a nearly $9.5 billion market in 2009. In 2005, the FDA received 275 combo product submissions, and an estimated 30% of new products under development today are combo products.

"For manufacturers, the convergence of devices and drugs or biologics also brings a host of new FDA testing guidelines, practices, and regulations unique to the development and production of combination products," he said.

The paper's contents include: Defining the Convergence, FDA Responsibility, QC Drug Release Criteria, Biologics, New Developments in FDA Thinking, and Future Considerations.

Download the free white paper at: http://www.microtestlabs.com/combinationpaper. For more information visit Microtest on the Web at http://www.microtestlabs.com, or call toll-free: 1-800-631-1680.

About Microtest

Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, biotechnology industries. Based in Agawam, Massachusetts, USA, the company's expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Steve Richter, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=42622


'/>"/>
SOURCE Microtest
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
2. Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers
3. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
4. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
5. 454 Sequencing(TM): Science Paper Suggests That Structural Variation Plays an Important Role in Genetic Variation
6. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
9. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, an industry-leading ... launch of its revamped and improved website. In an on-going effort to further ... website will better communicate how the company designs and delivers thorough, high-quality results ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Vice President for Public Policy for the National Organization for Rare Disorders (NORD). ... groups to ensure their voices are heard throughout the drug regulatory review process. ...
(Date:2/9/2016)... BERG, a biopharmaceutical company uncovering health ... announced the appointment of Jason Haddock ... Haddock brings to BERG over 20 years of ... senior financial functions at pharmaceutical companies, as well ... Niven R. Narain , BERG,s ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
Breaking Biology Technology:
(Date:2/2/2016)...   Parabon NanoLabs (Parabon) announced today ... Office and the Defense Forensics and Biometrics Agency ... company,s Snapshot Kinship Inference software for ... defense-related DNA forensics.  Although Snapshot is best known ... ancestry from DNA evidence), it also has the ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):